Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk

Byrne, D.J., Jagroop, I.A., Montgomery, H., Thomas, M., Mikhailidis, D.P., Milton, N.G.N. and Winder, A.F. 2002. Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk. Journal of Clinical Pathology. 55 (4), pp. 280-285.

TitleLipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk
AuthorsByrne, D.J., Jagroop, I.A., Montgomery, H., Thomas, M., Mikhailidis, D.P., Milton, N.G.N. and Winder, A.F.
Abstract

Aims: To investigate the proposal that lipoprotein (a) (Lp(a)) contributes to the acute phase response and thus possibly to the acute cardiac risks associated with major physical effort.

Methods/Results: Fit, healthy, British army recruits were reviewed at the beginning and the end of a 10 week programme of basic training concluding with an intense 48 hour military exercise. Final recruit assessment was staggered over the last week of training, giving rise to six recruit groups, with determination of Lp(a), C reactive protein (CRP), fibrinogen, albumin, and total creatine kinase values from 12 hours to five days after the final exercise. A clear acute phase response was seen following the final exercise, marked by a significant increase in circulating concentrations of fibrinogen and a reduction of albumin, and a trend with non-significant increases in CRP.

Conclusion: Lp(a) did not behave as an early marker of the acute response. Previous reports may have been confounded by concurrent disease in older subjects and by late sampling. Lp(a) determination for cardiovascular risk profiling is not confounded by associated physical effort. It is also unlikely that the acute risks of major physical effort are enhanced by any process involving Lp(a).

JournalJournal of Clinical Pathology
Journal citation55 (4), pp. 280-285
ISSN0021-9746
YearApr 2002
PublisherBMJ
Web address (URL)http://jcp.bmjjournals.com/content/55/4/280.abstract
Publication dates
PublishedApr 2002

Related outputs

Polymorphism of amyloid fibrils and their complexes with catalase
Milton, N.G.N. and Harris, J.R. 2014. Polymorphism of amyloid fibrils and their complexes with catalase. in: Uversky, V.N. and Lyubchenko, Y.L. (ed.) Bio-nanoimaging: protein misfolding and aggregation Boston Academic Press. pp. 255-262

Immunocytochemical staining of endogenous nuclear proteins with the HIS-1 anti-poly-histidine monoclonal antibody: a potential source of error in His-tagged protein detection
Chilumuri, A., Markiv, A. and Milton, N.G.N. 2014. Immunocytochemical staining of endogenous nuclear proteins with the HIS-1 anti-poly-histidine monoclonal antibody: a potential source of error in His-tagged protein detection. Acta Histochemica. 116 (6), pp. 1022-1028. https://doi.org/10.1016/j.acthis.2014.04.006

The neuroprotective role of catalase overexpression in SH-SY5Y cells against beta-amyloid and H2O2 toxicity
Chilumuri, A., Odell, M. and Milton, N.G.N. 2013. The neuroprotective role of catalase overexpression in SH-SY5Y cells against beta-amyloid and H2O2 toxicity. Alzheimer's & Dementia. 9 (4), p. P361.

Sulforaphane alters cerebral leukocyte endothelial cell interactions post global ischaemia reperfusion
Gillespie, S., Milton, N.G.N., Ashioti, M. and Gavins, F.N.E. 2013. Sulforaphane alters cerebral leukocyte endothelial cell interactions post global ischaemia reperfusion. FASEB Journal. 27, p. 687.18.

Kissorphin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus
Milton, N.G.N. 2013. Kissorphin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus.

Benzothiazole aniline-tetra(ethylene glycol) and 3-amino-1,2,4-triazole inhibit neuroprotection against amyloid peptides by catalase overexpression in vitro
Chilumuri, A., Odell, M. and Milton, N.G.N. 2013. Benzothiazole aniline-tetra(ethylene glycol) and 3-amino-1,2,4-triazole inhibit neuroprotection against amyloid peptides by catalase overexpression in vitro. ACS chemical neuroscience. 4 (11), pp. 1501-1512. https://doi.org/10.1021/cn400146a

The role of neurotransmitters in protection against amyloid-β toxicity by KiSS-1 overexpression in SH-SY5Y neurons
Chilumuri, A. and Milton, N.G.N. 2013. The role of neurotransmitters in protection against amyloid-β toxicity by KiSS-1 overexpression in SH-SY5Y neurons. ISRN Neuroscience. 2013 253210. https://doi.org/10.1155/2013/253210

Immunolocalization of kisspeptin associated with amyloid-β deposits in the pons of an Alzheimer’s disease patient
Chilumuri, A., Ashioti, M., Nercessian, A.N. and Milton, N.G.N. 2013. Immunolocalization of kisspeptin associated with amyloid-β deposits in the pons of an Alzheimer’s disease patient. Journal of Neurodegenerative Diseases. 2013 879710. https://doi.org/10.1155/2013/879710

Neuroprotective efficacy of the endogenous neuropeptide Urocortin in a oxygen-glucose deprivation model of transient cerebral ischaemia with reperfusion
Ashioti, M., Getting, S.J., Locke, I.C. and Milton, N.G.N. 2013. Neuroprotective efficacy of the endogenous neuropeptide Urocortin in a oxygen-glucose deprivation model of transient cerebral ischaemia with reperfusion. British Neuroscience Association 22nd Biennial Meeting. London 7th-10th April 2013

Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide
Milton, N.G.N. and Harris, J.R. 2013. Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide. Micron. 44, pp. 246-253. https://doi.org/10.1016/j.micron.2012.07.001

A phenotype–genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom
Camilleri, R., Scully, M., Thomas, M., Mackie, I.J., Liesner, R., Chen, W., Manns, K. and Machin, S.J. 2012. A phenotype–genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. Journal of Thrombosis and Haemostasis. 10 (9), pp. 1792-1801. https://doi.org/10.1111/j.1538-7836.2012.04852.x

Kisspeptin prevention of Amyloid-β Peptide neurotoxicity in vitro
Milton, N.G.N., Chilumuri, A., Rocha-Ferreira, E., Nercessian, A.N. and Ashioti, M. 2012. Kisspeptin prevention of Amyloid-β Peptide neurotoxicity in vitro. ACS chemical neuroscience. 3 (9), pp. 706-719. https://doi.org/10.1021/cn300045d

Kissorphin, a hexapeptide derivative of Kisspeptin, acts via Neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no Gonadotrophin-Releasing-Hormone releasing activity
Milton, N.G.N. 2012. Kissorphin, a hexapeptide derivative of Kisspeptin, acts via Neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no Gonadotrophin-Releasing-Hormone releasing activity. Endocrine Abstracts. 28, p. OC2.3.

In vitro activities of Kissorphin, a novel hexapeptide KiSS-1 derivative, in neuronal cells
Milton, N.G.N. 2012. In vitro activities of Kissorphin, a novel hexapeptide KiSS-1 derivative, in neuronal cells. Journal of Amino Acids. 2012 691463. https://doi.org/10.1155/2012/691463

Introduction and technical survey: protein aggregation and fibrillogenesis
Harris, J.R. and Milton, N.G.N. 2012. Introduction and technical survey: protein aggregation and fibrillogenesis. Subcellular Biochemistry. 65, pp. 3-25. https://doi.org/10.1007/978-94-007-5416-4_1

Thrombotic thrombocytopenic purpura (TTP) and pregnancy in the UK: identification of subtype, management and outcome of subsequent pregnancies
Thomas, M., Camilleri, R., Machin, S.J., Clark, A., Creagh, D., Evans, G. and Scully, M. 2011. Thrombotic thrombocytopenic purpura (TTP) and pregnancy in the UK: identification of subtype, management and outcome of subsequent pregnancies. British society for haemostasis and thrombosis (BSHT) scientific meeting. Brighton, UK

Thrombotic Thrombocytopenic Purpura (TTP) and pregnancy in the UK: indentification of subtype, manangement and outcome of subsequent pregnancies
Thomas, M., Camilleri, R., Machin, S.J., Clark, A., Creagh, D., Evans, G. and Scully, M. 2011. Thrombotic Thrombocytopenic Purpura (TTP) and pregnancy in the UK: indentification of subtype, manangement and outcome of subsequent pregnancies. XXIIIrd Congress of the International Society on Thrombosis and Haemostasis (ISTH),. Kyoto, Japan

Kissorphin Peptides used in the treatment of Alzheimer’s Disease, Creutzfeldt Jakob Disease or Diabetes Mellitus P.
Milton, N.G.N. 2011. Kissorphin Peptides used in the treatment of Alzheimer’s Disease, Creutzfeldt Jakob Disease or Diabetes Mellitus P.

Kissorphin Peptides used in the treatment of Alzheimer’s Disease, Creutzfeldt Jakob Disease or Diabetes Mellitus P.
Milton, N.G.N. 2011. Kissorphin Peptides used in the treatment of Alzheimer’s Disease, Creutzfeldt Jakob Disease or Diabetes Mellitus P.

Meta-analysis of sex difference in testosterone levels in umbilical cord blood
Barry, J.A., Hardiman, P.J., Siddiqui, M.R. and Thomas, M. 2011. Meta-analysis of sex difference in testosterone levels in umbilical cord blood. Journal of Obstetrics and Gynaecology. 31 (8), pp. 697-702.

Human islet amyloid polypeptide fibril binding to catalase: a transmission electron microscopy and microplate study
Milton, N.G.N. and Harris, J.R. 2010. Human islet amyloid polypeptide fibril binding to catalase: a transmission electron microscopy and microplate study. ScientificWorldJournal. 10, pp. 879-893. https://doi.org/10.1100/tsw.2010.73

Cholesterol in Alzheimer's disease and other amyloidogenic disorders
Harris, J.R. and Milton, N.G.N. 2010. Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcellular Biochemistry. 51, pp. 47-75. https://doi.org/10.1007/978-90-481-8622-8_2

Polymorphism of amyloid-ß fibrils and its effects on human erythrocyte catalase binding
Milton, N.G.N. and Harris, J.R. 2009. Polymorphism of amyloid-ß fibrils and its effects on human erythrocyte catalase binding. Micron. 40 (8), pp. 800-810. https://doi.org/10.1016/j.micron.2009.07.006

Homocysteine inhibits hydrogen peroxide breakdown by catalase
Milton, N.G.N. 2008. Homocysteine inhibits hydrogen peroxide breakdown by catalase. Open Enzyme Inhibition Journal. 1, pp. 34-41. https://doi.org/10.2174/1874940200801010034

Interactions between amyloid-ß and enzymes
Milton, N.G.N. 2006. Interactions between amyloid-ß and enzymes. in: Harris, J.R., Graham, J. and Rickwood, D. (ed.) Cell biology protocols Chichester Wiley. pp. 359-363

Anti-sense peptides
Milton, N.G.N. 2006. Anti-sense peptides. in: Harris, J.R., Graham, J. and Rickwood, D. (ed.) Cell biology protocols Chichester Wiley. pp. 353-358

Amyloid-ß phosphorylation
Milton, N.G.N. 2006. Amyloid-ß phosphorylation. in: Harris, J.R., Graham, J. and Rickwood, D. (ed.) Cell biology protocols Chichester Wiley. pp. 364-368

Phosphorylated Amyloid-ß 1-43 protein and its use in the treatment of Alzheimer's disease
Milton, N.G.N. 2005. Phosphorylated Amyloid-ß 1-43 protein and its use in the treatment of Alzheimer's disease.

Phosphorylated amyloid-ß: the toxic intermediate in Alzheimer's disease neurodegeneration
Milton, N.G.N. 2005. Phosphorylated amyloid-ß: the toxic intermediate in Alzheimer's disease neurodegeneration. Subcellular Biochemistry. 38, pp. 381-402.

Peptides for use in the treatment of Alzheimer's disease
Milton, N.G.N. 2004. Peptides for use in the treatment of Alzheimer's disease.

Role of hydrogen peroxide in the aetiology of Alzheimer's disease: implications for treatment
Milton, N.G.N. 2004. Role of hydrogen peroxide in the aetiology of Alzheimer's disease: implications for treatment. Drugs & Aging. 21 (2), pp. 81-100.

Peptides for use in the treatment of Alzheimer's disease
Milton, N.G.N. 2003. Peptides for use in the treatment of Alzheimer's disease.

Anandamide and noladin ether prevent neurotoxicity of the human amyloid-ß peptide
Milton, N.G.N. 2002. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-ß peptide. Neuroscience Letters. 332 (2), pp. 127-130. https://doi.org/10.1016/S0304-3940(02)00936-9

The amyloid-β peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity
Milton, N.G.N. 2002. The amyloid-β peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity. Neuroscience Letters. 322 (2), pp. 131-133. https://doi.org/10.1016/S0304-3940(02)00081-2

Peptides for use in the treatment of Alzheimer's disease
Milton, N.G.N. 2002. Peptides for use in the treatment of Alzheimer's disease.

Phosphorylation of amyloid-ß at the serine 26 residue by human cdc2 kinase
Milton, N.G.N. 2001. Phosphorylation of amyloid-ß at the serine 26 residue by human cdc2 kinase. NeuroReport. 12 (17), pp. 3839-3844.

Inhibition of catalase activity with 3-amino-triazole enhances the cytotoxicity of the Alzheimer’s amyloid-ß peptide
Milton, N.G.N. 2001. Inhibition of catalase activity with 3-amino-triazole enhances the cytotoxicity of the Alzheimer’s amyloid-ß peptide. NeuroToxicology. 72 (6), pp. 767-774. https://doi.org/10.1016/S0161-813X(01)00064-X

Identification of amyloid-ß binding sites using an antisense peptide approach
Milton, N.G.N., Mayor, N.P. and Rawlinson, J. 2001. Identification of amyloid-ß binding sites using an antisense peptide approach. NeuroReport. 12 (11), pp. 2561-2566.

Message-passing computing with Java: performance evaluation and comparisons
Getov, Vladimir, Lu, Q., Thomas, M. and Williams, M. 2001. Message-passing computing with Java: performance evaluation and comparisons. in: Proceedings of the Ninth Euromicro Workshop on Parallel and Distributed Processing, 2001 IEEE . pp. 173-177

Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training
Montgomery, H., Clarkson, P., Barnard, M.L., Bell, J.D., Brynes, A.E., Hajnal, J.V., Hemingway, H., Mercer, D., Jarman, P., Marshall, R., Prasad, K., Rayson, M., Saeed, N., Thomas, E.L., Jubb, M., World, M., Dollery, C., Talmud, P. and Humphries, S.E. 1999. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. The Lancet. 353 (9152), pp. 541-545. https://doi.org/10.1016/S0140-6736(98)07131-1

Human gene for physical performance
Montgomery, H., Marshall, R., Hemingway, H., Myerson, S., Clarkson, P., Dollery, C., Hayward, M., Holliman, D.E., Jubb, M., World, M., Thomas, E.L., Brynes, A.E., Saeed, N., Barnard, M.L., Bell, J.D., Prasad, K., Rayson, M., Talmud, P. and Humphries, S.E. 1998. Human gene for physical performance. Nature. 393 (6682), pp. 221-222. https://doi.org/10.1038/30374

Permalink - https://westminsterresearch.westminster.ac.uk/item/93v37/lipoprotein-a-does-not-participate-in-the-early-acute-phase-response-to-training-or-extreme-physical-activity-and-is-unlikely-to-enhance-any-associated-immediate-cardiovascular-risk


Share this

Usage statistics

123 total views
0 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.